Wellinks Names Dr. Abi Sundaramoorthy as Chief Medical Officer

April 29, 2022
Table of Contents

Wellinks, a digital healthcare company offering the first-ever integrated, virtual Chronic Obstructive Pulmonary Disease (COPD) management solution, today announced that Dr. Abi Sundaramoorthy has joined the leadership team as Chief Medical Officer.

Dr. Sundaramoorthy brings to Wellinks over ten years of experience from across the full spectrum of healthcare, working to promote high-value care for both hospital systems and private companies, and was recently named a Top 25 Emerging Leader by Modern Healthcare. As a practicing physician, Dr. Sundaramoorthy served in several leadership positions with University Hospitals Health System in Ohio, including as System Clinical Value Officer where she oversaw an accountable care organization within a health system covering over 1.2 million patient lives, as well as Chief Medical Officer. While at University Hospitals, she received her MBA from Baldwin Wallace University, where she focused her studies on how to align incentives across healthcare to improve quality and outcomes. Most recently, she served as the Executive Vice President of Clinical Enterprise at Somatus, where she focused on delivering continuous, whole-person care to patients with chronic kidney disease. Dr. Sundaramoorthy also continues practicing as a hospitalist with Pioneer Medical Group in Tampa, Fl. and as an Assistant Professor at University of South Florida College of Nursing.

"Dr. Sundaramoorthy has a proven track record of leading successful clinical programs, fostering deep connections across the scientific and medical communities to put the patient first, and a depth of experience in value-based chronic disease management," said Alex Waldron, CEO of Wellinks. "We are thrilled to welcome her to the Wellinks team to support our work making COPD care more accessible, affordable, and effective."

In her role as Chief Medical Officer with Wellinks, Dr. Sundaramoorthy will apply her expertise to the clinical strategic direction for the company and help to shape the development and deployment of Wellinks' offering in close partnership with the product team. She will also be responsible for leading the medical staff and care teams, managing to quality goals, and supporting ongoing business and clinical development efforts.

"Wellinks' patient-centered approach to virtual-first COPD care aligns perfectly with my personal values and philosophy of care, and I am excited to continue advancing high-quality care rooted in value with this incredible team," said Dr. Sundaramoorthy. "I saw firsthand in my hospital practice how COPD patients have been left behind by the existing delivery system, and I look forward to making sure they have access to the same kind of innovative, virtual care that has revolutionized care in other chronic disease areas."

This strategic addition to the company's leadership team comes on the heels of a period of great momentum for Wellinks. Just last month, peer-reviewed research in the Journal of Medical Internet Research found that older Wellinks users were highly engaged and satisfied managing their COPD with its virtual-first solution. Additionally, Wellinks announced the closing of a $25M funding round in November 2021 to expand the first integrated virtual COPD management solution to more patients.

Wellinks, a digital healthcare company offering the first-ever integrated, virtual Chronic Obstructive Pulmonary Disease (COPD) management solution, today announced that Dr. Abi Sundaramoorthy has joined the leadership team as Chief Medical Officer.

Dr. Sundaramoorthy brings to Wellinks over ten years of experience from across the full spectrum of healthcare, working to promote high-value care for both hospital systems and private companies, and was recently named a Top 25 Emerging Leader by Modern Healthcare. As a practicing physician, Dr. Sundaramoorthy served in several leadership positions with University Hospitals Health System in Ohio, including as System Clinical Value Officer where she oversaw an accountable care organization within a health system covering over 1.2 million patient lives, as well as Chief Medical Officer. While at University Hospitals, she received her MBA from Baldwin Wallace University, where she focused her studies on how to align incentives across healthcare to improve quality and outcomes. Most recently, she served as the Executive Vice President of Clinical Enterprise at Somatus, where she focused on delivering continuous, whole-person care to patients with chronic kidney disease. Dr. Sundaramoorthy also continues practicing as a hospitalist with Pioneer Medical Group in Tampa, Fl. and as an Assistant Professor at University of South Florida College of Nursing.

"Dr. Sundaramoorthy has a proven track record of leading successful clinical programs, fostering deep connections across the scientific and medical communities to put the patient first, and a depth of experience in value-based chronic disease management," said Alex Waldron, CEO of Wellinks. "We are thrilled to welcome her to the Wellinks team to support our work making COPD care more accessible, affordable, and effective."

In her role as Chief Medical Officer with Wellinks, Dr. Sundaramoorthy will apply her expertise to the clinical strategic direction for the company and help to shape the development and deployment of Wellinks' offering in close partnership with the product team. She will also be responsible for leading the medical staff and care teams, managing to quality goals, and supporting ongoing business and clinical development efforts.

"Wellinks' patient-centered approach to virtual-first COPD care aligns perfectly with my personal values and philosophy of care, and I am excited to continue advancing high-quality care rooted in value with this incredible team," said Dr. Sundaramoorthy. "I saw firsthand in my hospital practice how COPD patients have been left behind by the existing delivery system, and I look forward to making sure they have access to the same kind of innovative, virtual care that has revolutionized care in other chronic disease areas."

This strategic addition to the company's leadership team comes on the heels of a period of great momentum for Wellinks. Just last month, peer-reviewed research in the Journal of Medical Internet Research found that older Wellinks users were highly engaged and satisfied managing their COPD with its virtual-first solution. Additionally, Wellinks announced the closing of a $25M funding round in November 2021 to expand the first integrated virtual COPD management solution to more patients.

Driving Better Outcomes
COPD foundation logo and Wellinks logo - Wellinks Images

Wellinks is excited to announce the final results of ASPIRE – a clinical trial conducted with the COPD Foundation to assess the impact of Wellinks on quality of life, engagement and satisfaction among COPDF members living with COPD.

Circle with 3 images- laptop, smartphone and call screenshot - Wellinks Images
Each participant received personalized health coaching, virtual pulmonary rehabilitation, and monitoring through connected devices and a patient-facing app.

The study enrolled 141 members in the trial, with 119 completing the 24-week study. These results demonstrate sustained engagement, satisfaction, and clinical response with Wellinks.

Interested in learning more about Wellinks?

Request a Demo Today

Wellinks Engagement at 24 Weeks
(n = 141)

61%
Finger pressing the "Join" button - Wellinks Images
Enrollment Rate

Proportion successfully enrolled out of all who were interested and eligible

84%
Two hands shaking - Wellinks Images
Retention Rate

Proportion who remained enrolled in the study at 24 weeks

These results were demonstrated in a population with...

Web stats - Wellinks Images

High Member Satisfaction at 24 Weeks

  • Over 81% said Wellinks helped them better manage their COPD
  • Over 92% found Wellinks to be valuable
  • Over 83% said Wellinks helped them learn more about their COPD
+64
Net Promoter Score*
* Net Promoter Score (NPS) is a customer loyalty and satisfaction measurement taken from asking customers how likely they are to recommend your product. NPS scores range from -100 to +100. This NPS is based on responses from those who continued contact with coaches, representative of the Wellinks clinical model.

Improved Clinical Outcomes at 24 Weeks

Healthcare icon - Wellinks Images
Wellinks demonstrated sustained improvements in COPD self-efficacy as measured by the COPD Self-efficacy Scale (CSES) at 24 weeks.
Respiratory icon - Wellinks Images
Self-efficacy is a measure of how confident an individual is in managing their COPD and addressing shortness of breath.
Magnifying glass icon - Wellinks Images

One-third of participants demonstrated improvements in Modified Medical Research Council dyspnea score. mMRC is a measure of breathlessness that is associated with risk of future exacerbations.

Sign up to stay updated on ASPIRE and Wellinks.

Thank you! Stay tuned for more Wellinks news soon.

Oops! Something went wrong while submitting the form.
*By providing your email address, you agree to opt into receiving our Wellinks marketing emails.
You can unsubscribe at any time. Your information will be held confidential.